Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted

Reem Ali(Hamad bin Khalifa University), Dindial Ramotar(Université de Montréal), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Abdallah Alhaj Sulaiman(Hamad bin Khalifa University), Mustapha Aouida(Hamad bin Khalifa University)
International Journal of Molecular Sciences
June 29, 2022
10.3390/ijms23137241
Cited by 76

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
|The Lancet Oncology|2015|282